Aceto (ACET) Releases Earnings Results, Misses Expectations By $0.54 EPS

Aceto (NASDAQ:ACET) issued its earnings results on Thursday. The company reported ($0.59) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.54), RTT News reports. Aceto had a negative net margin of 34.41% and a positive return on equity of 0.55%. The business had revenue of $164.41 million during the quarter. During the same period last year, the business earned $0.30 EPS.

Aceto stock traded down $0.23 during midday trading on Friday, hitting $1.80. 996,398 shares of the stock were exchanged, compared to its average volume of 252,886. Aceto has a fifty-two week low of $1.53 and a fifty-two week high of $11.98. The stock has a market cap of $63.14 million, a P/E ratio of 45.00 and a beta of 1.58. The company has a current ratio of 1.66, a quick ratio of 1.21 and a debt-to-equity ratio of 3.18.

Separately, ValuEngine upgraded shares of Aceto from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd. Five analysts have rated the stock with a sell rating, The stock presently has an average rating of “Sell” and an average price target of $2.00.

In related news, Chairman Albert L. Eilender sold 10,700 shares of the firm’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $3.29, for a total transaction of $35,203.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 32,187 shares of company stock valued at $102,225. 4.10% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at

About Aceto

Aceto Corporation engages in the development, marketing, sale, and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, specialty performance chemicals, and agricultural protection products. The company operates in three segments: Human Health, Pharmaceutical Ingredients, and Performance Chemicals.

Read More: Why is Cost of Capital Important?

Earnings History for Aceto (NASDAQ:ACET)

Receive News & Ratings for Aceto Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aceto and related companies with's FREE daily email newsletter.

Leave a Reply